SCHEMBL6775667

SCHEMBL6775667

Cn1ccc2c1C(=O)CCN(CCCN1CCN(c3ccc(O)cc3)CC1)C2=O

nearest known ligand 0.50

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 12/20 0.50
DRD2 P14416 5/20 0.42
DRD1 P21728 3/20 0.42
DRD5 P21918 2/20 0.42
HTR1A P08908 2/20 0.42
HTR7 P34969 2/20 0.41
DRD4 P21917 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6773605 0.89 DRD3 (0.53) DRD3DRD2DRD1DRD5HTR1A
SCHEMBL6619452 0.89 DRD3 (0.50) DRD3DRD2DRD1DRD4
SCHEMBL6771012 0.89 DRD3 (0.54) DRD3DRD2DRD1DRD5HTR1A
SCHEMBL6772864 0.88 DRD3 (0.47) DRD3DRD2DRD1DRD5HTR1A
SCHEMBL6772866 0.88 DRD3 (0.47) DRD3DRD2DRD1DRD5HTR1A
SCHEMBL6771925 0.88 DRD3 (0.67) DRD3DRD2DRD1HTR1AHTR7
SCHEMBL6779855 0.87 DRD3 (0.50) DRD3DRD2DRD5HTR1ADRD4
SCHEMBL6774507 0.86 DRD3 (0.47) DRD3DRD2HTR1AHTR7DRD4
SCHEMBL6776156 0.83 DRD3 (0.53) DRD3DRD2DRD1DRD5HTR1A
SCHEMBL6780422 0.83 DRD2 (0.48) DRD3DRD2HTR1ADRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713634-B2 SEROTONIN RECEPTOR ANTAGONIST DAIICHI SUNTORY PHARMA CO., LTD. (JP) 2004-03-30 US disclosed
US-20030166926-A1 Pyrroloazepine derivatives SUNTORY LIMITED (JP) 2003-09-04 US disclosed
US-6489473-B2 FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION SUNTORY LIMITED (JP) 2002-12-03 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020072515-A1 Pyrroloazepine derivatives SUNTORY LIMITED (JP) 2002-06-13 US disclosed
EP-0807632-B1 PYRROLOAZEPINE DERIVATIVES SUNTORY LTD (JP) 2002-04-17 EP disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed
US-6258805-B1 TREATMENT OF BRAIN DISORDERS AND HYPERTENSION SUNTORY LIMITED (JP) 2001-07-10 US disclosed
EP-0807632-A1 PYRROLOAZEPINE DERIVATIVES SUNTORY LIMITED (JP) 1997-11-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072515-A1 Pyrroloazepine derivatives TPH2, HTR2A, HTR2C DRD3 165/4885DRD2 34/4885DRD1 141/4885
US-20030166926-A1 Pyrroloazepine derivatives TPH2, HTR2A, HTR2C DRD3 173/4885DRD2 34/4885DRD1 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.